Vector Therapeutics

Attralus (formerly Vector Therapeutics) is a clinical-stage biopharmaceutical company dedicated to improving the lives of patients with systemic amyloidosis. The company leverages its proprietary Pan-Amyloid Imaging and Therapeutics (PAT) platform to develop products that bind to all types of amyloid fibrils, the underlying cause of the disease. Their lead program, AT-01, is a first-in-class pan-amyloid imaging agent currently in Phase 2 clinical trials, designed to detect and monitor amyloid deposits across multiple organs. Additionally, Attralus is advancing a pipeline of therapeutic candidates, including AT-02 and AT-03, which are engineered to promote the clearance of amyloid fibrils through the body's natural immune response. By addressing the high unmet need in diseases like ATTR and AL amyloidosis, Attralus aims to provide earlier diagnosis and more effective treatments for patients.